Implementation of Pharmacogenetics to Individualize Treatment Regimens for Children with Acute Lymphoblastic Leukemia
| Autor: | Nathalie K. Zgheib, Dimitri Maamari, Omran Saifi, Habib El-Khoury, Samar Muwakkit |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Pharmacology Oncology Drug medicine.medical_specialty Candidate gene Treatment regimen business.industry Lymphoblastic Leukemia media_common.quotation_subject 03 medical and health sciences 030104 developmental biology 0302 clinical medicine 030220 oncology & carcinogenesis Internal medicine medicine Molecular Medicine Dose reduction Disease management (health) business Childhood Acute Lymphoblastic Leukemia Pharmacogenetics media_common |
| Zdroj: | Pharmacogenomics and Personalized Medicine. 13:295-317 |
| ISSN: | 1178-7066 |
| DOI: | 10.2147/pgpm.s239602 |
| Popis: | Despite major advances in the management and high cure rates of childhood acute lymphoblastic leukemia (ALL), patients still suffer from many drug-induced toxicities, sometimes necessitating dose reduction, or halting of cytotoxic drugs with a secondary risk of disease relapse. In addition, investigators have noted significant inter-individual variability in drug toxicities and disease outcomes, hence the role of pharmacogenetics (PGx) in elucidating genetic polymorphisms in candidate genes for the optimization of disease management. In this review, we present the PGx data in association with main toxicities seen in children treated for ALL in addition to efficacy, with a focus on the most plausible germline PGx variants. We then follow with a summary of the highest evidence drug-gene annotations with suggestions to move forward in implementing preemptive PGx for the individualization of treatment regimens for children with ALL. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|